Article
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
Cancer - 1 Aug 2010
Velev Nikolai, Cortes Jorge, Champlin Richard, Jones Dan, Rondon Gabriela, Giralt Sergio, Borthakur Gautam, Kantarjian Hagop M, De Lima Marcos
Abstract excerpt
BACKGROUND: Resistance to tyrosine kinase inhibitor (TKIs) therapy is associated with the development of kinase domain mutations. Although many imatinib-resistant mutations respond well to second-generation TKIs, the threonine-to-isoleucine mutation at codon 315 of the breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene protein fusion Bcr-Abl (T315I) is insensitive to all currently available...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.